Philippines FDA Approval - Oncotherm Kft.

Oncotherm is pleased to announce that its EHY-2030 oncological hyperthermia device has received approval from the Philippines Food and Drug Administration (FDA).

This regulatory clearance confirms that the EHY-2030 meets the applicable safety, quality, and performance requirements, allowing its clinical use in the Philippines.

The approval represents an important milestone in Oncotherm’s international expansion strategy and strengthens the company’s presence in the Southeast Asian medical device market. It also underlines Oncotherm’s long-standing commitment to delivering safe, effective, and innovative oncological solutions worldwide.

This achievement supports our mission to make advanced oncological hyperthermia accessible to a broader range of patients and healthcare providers globally.

Oncotherm would like to express its sincere appreciation to all those who contributed to achieving this regulatory approval.

In particular, we would like to extend our special thanks to the Life1 Corporation team and its Managing Director,
Dr. Albert Zarate, for their valuable cooperation and dedicated support throughout the registration process.

Oncotherm is pleased to announce that its EHY-2030 oncological hyperthermia device has received approval from the Philippines Food and Drug Administration (FDA).

Oncotherm would like to express its sincere appreciation to all those who contributed to achieving this regulatory approval.

In particular, we would like to extend our special thanks to the Life1 Corporation team and its Managing Director, Dr. Albert Zarate, for their valuable cooperation and dedicated support throughout the registration process.

Weitere Neuigkeiten

In particular, we would like to extend our special thanks to the Life1 Corporation team and its Managing Director,
Dr. Albert Zarate, for their valuable cooperation and dedicated support throughout the registration process.